ClinicalTrials.gg
RecruitingNCT05593848Updated May 25, 2023

Intratissue Percutaneous Electrolysis vs Dry Needling in Myofascial Pain Syndrome of Shoulder Pain

An interventional study of Intratissue Percutaneous Electrolysis and Dry Needling in Shoulder Pain and Myofascial Pain Syndrome, sponsored by University of Salamanca. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-05-25.

Sponsored by University of Salamanca · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2023, 3 years 3 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Feb 2022, registered Oct 2022).
  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Shoulder Pain with a site in Spain — 10 open to participants now, 10 under way, none of them phase 3. Shoulder Pain · Spain.

Planned enrollment
30th of 49
42 · median 50
Started
2022
with 2 others
No phase
47 of 52
10 open now
Registered
27th of 52
by date

Among the 52 studies in Shoulder Pain with a site in Spain, this one is the 30th largest by planned enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2022, is one of 47 with no phase, and was the 27th registered.

Shoulder Pain

738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.

Browse Shoulder Pain studies →

Open to participants now

10 of the 52 studies in Shoulder Pain with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Shoulder Pain with a site in Spain, or all of them as a file.
02

Study summary

This is a parallel-group randomised clinical trial:

Primary purpose: To analyse the clinical changes produced by two different physiotherapy treatments (Intratissue Percutaneous Electrolysis and Dry Needling) for myofascial trigger points in the infraspinatus muscle in subjects with non-specific shoulder pain.

Hypothesis: A physiotherapy treatment including Intratissue Percutaneous Electrolysis therapy present greater benefits in terms of pain reduction and increased mobility and functionality rather than Dry Needling treatment in subjects with non-specific shoulder pain.

The intervention consisted of 3 treatment sessions, different according to the group, once a week. Seven evaluation points were performed, two pre-intervention evaluations one week apart and after the second one the first treatment session was performed. The third and fourth assessments were prior to the second and third treatment sessions, one week apart. The fifth, sixth and seventh assessments were conducted one week, one month and two months after the last treatment session in each group.

03

Conditions studied

  • Shoulder Pain
  • Myofascial Pain Syndrome

Keywords

  • Intratissue Percutaneous Electrolysis
  • Dry Needling
  • Myofascial trigger points
  • infraspinatus muscle
  • non-specific shoulder pain
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both male and female patients suffering from shoulder pain during at least three months before intervention protocol starts.
  • Patients with free passive range of movement and at least 15 degrees active external rotation in the affected shoulder.
  • Patients willing to participate in the study and return for all scheduled follow-up visits.
  • Patient is capable of giving, and has given, written .

Exclusion criteria

Exclusion Criteria:

  • Patients with a previous medical diagnosis (tendon rupture, bursitis, etc.) or a traumatic history that justifies shoulder pain.
  • Patients with unstable or uncontrolled angina, uncontrolled heart failure, or serious uncontrolled ventricular arrhythmias.
  • Patients allergic to metal or those who have needle phobia.
  • Patient that has participated in any other shoulder pain treatment research study within 30 days prior.
  • Patients that had prior shoulder surgery.
  • Patients that are currently being treated with a narcotic or NSAIDs and/or has used analgesics or NSAIDs within the 72 hours prior.
  • Patients that has a known bleeding disorder or that are currently being treated with anticoagulant therapy.
  • Pregnant women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Experimental Group (Intratissue Percutaneous Electrolysis Group)

    The treatment to be performed in the Intratissue percutaneus electrolysis Group will consist of: 1. Palpation and localization of the myofascial trigger points in the infraspinatus muscle of the affected shoulder. 2. Application of the ultrasound-guided intratissue percutaneus electroysis technique (1 or 2 approaches) on the myofascial trigger points with the greatest clinical manifestations for the subject. The needle will remain at intramuscular level without movement and a galvanic current discharge will be applied in the area, through the needle, whose intensity will oscillate between 0.5 and 3 milliAmperes (mA). 3. Performance of an eccentric work protocol of the infraspinatus muscle to reduce post-puncture pain.

    Procedure: Intratissue Percutaneous Electrolysis

  • Active comparator
    Active Control Group (Dry Needling Group)

    The treatment to be performed in the Dry Needling Group will consist of: 1. palpation and localization of myofascial trigger points in the infraspinatus muscle of the affected shoulder. 2. Application of the ultrasound-guided dry needling technique (1 or 2 approaches) on the myofascial trigger points with major clinical manifestations for the subject. The physiotherapist will move the needle into the muscle using Hong's rapid entry and exit technique. 3. Performance of an eccentric work protocol of the infraspinatus muscle to reduce post-puncture pain.

    Procedure: Dry Needling

Interventions

  • ProcedureIntratissue Percutaneous Electrolysis

    Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided Intratissue Percutaneous Electrolysis in the myofascial trigger points of the infraspinatus muscle

  • ProcedureDry Needling

    Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided dry needling in the myofascial trigger points of the infraspinatus muscle

06

What researchers measure

Primary outcomes

  1. Changes in Pain intensity, before, during and after the intervention

    Numerical pain rating scale (score 0-10 points)

    Time frame: 4 months (7 points)

Secondary outcomes

  1. Changes in Shoulder flexion range of motion, before, during and after the intervention

    The range of motion in flexion will be measured with an inclinometer to assess changes in the mobility to shoulder pain subjects

    Time frame: 4 months (7 points)

  2. Changes in Shoulder external rotation range of motion, before, during and after the intervention

    The range of motion in external rotation will be measured with an inclinometer to assess changes in the mobility to shoulder pain subjects

    Time frame: 4 months (7 points)

  3. Changes in Pressure pain threshold at proximal myofascial trigger point of the infraspinatus muscle, before, during and after the intervention

    The pressure threshold will be recorded using a digital algometer.

    Time frame: 4 months (7 points)

  4. Changes in Pressure pain threshold at distal myofascial trigger point of the infraspinatus muscle, before, during and after the intervention

    The pressure threshold will be recorded using a digital algometer (Pain Test™ FPIX 10)

    Time frame: 4 months (7 points)

  5. Changes in Strength in shoulder external rotation before, during and after the intervention

    The strength will be recorded with wireless MicroFET 2: Hand-held dynamometer for force assessment.

    Time frame: 4 months (7 points)

  6. Changes in Hand grip strength, before, during and after the intervention

    The strength will be recorded with Jamar Plus: Digital dynamometer to assess grip strength.

    Time frame: 4 months (7 points)

  7. Changes in Disability and functionality of the upper limb, before, during and after the intervention

    To measure the upper limb disability and functionality we will use the Disabilities of the Arm, Shoulder and Hand (DASH), which is a validated questionnaire that measures the functionality and disability that shoulder pain generates in the subject.

    Time frame: 4 months (7 points)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jul 2023, 17 months after the start.

Of 351 non-industry interventional studies with no phase under Shoulder Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 17 months is above that.

Counting every sponsor, half of 356 studies reached it within 11 months; a quarter within 4 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2022
First posted
Oct 25, 2022
StartActual
Feb 8, 2022
Primary completionEst.
Jul 30, 2023
CompletionEst.
Jul 30, 2023
Last update
May 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05593848
Responsible party
Roberto Méndez Sánchez (Professor, PhD, University of Salamanca) — Principal investigator
First posted
Oct 25, 2022
Start date
Feb 8, 2022
Primary completion
Jul 30, 2023 (estimated)
Completion
Jul 30, 2023 (estimated)
Last update
May 25, 2023

Study contacts

Roberto Méndez-Sánchez, PhD
Contact
ro_mendez@usal.es
+34 923294500 ext. 3201
Roberto Méndez-Sánchez
principal investigator · University of Salamanca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion